24-Jul-2026
Natera’s New ctDNA-Guided Immunotherapy Trial Could Redefine Cancer Treatment Cycles
TipRanks (Fri, 24-Jul 12:33 PM ET)
Natera (NTRA) Gets a Buy from BTIG
TipRanks (Thu, 23-Jul 7:38 AM ET)
Bernstein Sticks to Their Buy Rating for Natera (NTRA)
TipRanks (Thu, 23-Jul 3:55 AM ET)
Business Wire (Wed, 22-Jul 6:00 AM ET)
Cathie Wood’s ARK Invest adds another $57M to SpaceX, sells $39M stake in AMD
Seeking Alpha News (Mon, 20-Jul 7:05 AM ET)
Finalized MolDx LCD Includes Expanded Coverage for Natera's Prospera Portfolio
Business Wire (Thu, 16-Jul 6:35 PM ET)
Natera Announces IVDR Certification for Signatera Across Multiple Cancers
Business Wire (Thu, 9-Jul 6:00 AM ET)
Business Wire (Mon, 6-Jul 6:00 AM ET)
Business Wire (Mon, 29-Jun 6:00 AM ET)
Business Wire (Thu, 25-Jun 7:00 AM ET)
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Natera trades on the NASDAQ stock market under the symbol NTRA.
As of July 24, 2026, NTRA stock price declined to $261.99 with 682,238 million shares trading.
NTRA has a beta of 0.78, meaning it tends to be less sensitive to market movements. NTRA has a correlation of 0.05 to the broad based SPY ETF.
NTRA has a market cap of $37.52 billion. This is considered a Large Cap stock.
Last quarter Natera reported $697 million in Revenue and -$.60 earnings per share. This beat revenue expectation by $80 million and missed earnings estimates by -$.05.
In the last 3 years, NTRA traded as high as $288.04 and as low as $36.90.
The top ETF exchange traded funds that NTRA belongs to (by Net Assets): VTI, VB, VBK, VXF, IBB.
NTRA has outperformed the market in the last year with a return of +85.7%, while the SPY ETF gained +17.7%. In the last 3 month period, NTRA beat the market returning +28.6%, while SPY returned +3.8%. However, in the most recent 2 weeks NTRA has underperformed the stock market by returning -2.9%, while SPY returned -2.1%.
NTRA support price is $257.43 and resistance is $271.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NTRA shares will trade within this expected range on the day.